Recuvyra

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Download Patient Information leaflet (PIL)
12-07-2017
Download Summary of Product characteristics (SPC)
12-07-2017
Download Public Assessment Report (PAR)
12-07-2017

Active ingredient:

фентанил

Available from:

Eli Lilly and Company Limited 

ATC code:

QN02AB03

INN (International Name):

fentanyl

Therapeutic group:

Кучета

Therapeutic area:

Нервна система

Therapeutic indications:

За контролиране на болката, свързани с ортопедични и хирургия на меките тъкани при кучета.

Product summary:

Revision: 4

Authorization status:

Отменено

Authorization date:

2011-10-06

Patient Information leaflet

                                Лекарствен продукт, който вече не е
разрешен за употреба
20
B. ЛИСТОВКА
Лекарствен продукт, който вече не е
разрешен за употреба
21
ЛИСТОВКА ЗА:
Recuvyra 50 mg/ml трансдермален разтвор за
кучета
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА
УПОТРЕБА И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА
РАЗЛИЧНИ
Притежател на лиценза за употреб а:
Eli Lilly & Company Ltd
Elanco Animal Health
Lilly House
Priestley Road Basingstoke, Hampshire RG24 9NL
Великобритания
Производител, отговорен за
освобождаване на партидата:
McGregor Cory
Cherwell 2
Middleton Close
Banbury, Oxfordshire, OX16 4RS
Великобритания
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Recuvyra 50 mg/ml трансдермален разтвор за
кучета
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА СУБСТАНЦИЯ И
ЕКСЦИПИЕНТИТЕ
Recuvyra е прозрачен, безцветен до
светложълт разтвор, съдържащ 50 mg
фентанил (активна
субстанция) на милилитър от разтвора.
Recuvyra съдържа също така и октил
салицилат и
изопропилов алкохол. Recuvyra се доставя
на Вашия ветеринарен лекар в бутилк
а от жълто
стъкло, съдържаща 10 ml от продукта.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Recuvyra контролира болката при кучета,
които са били подложени на тежка
ортопедична операция или операция на
меки тъкани.
5.
ПРОТИВОПОКАЗАНИЯ
На Вашето куче не трябва д
                                
                                Read the complete document

Summary of Product characteristics

                                Лекарствен продукт, който вече не е
разрешен за употреба
1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Recuvyra 50 mg/ml трансдермален разтвор за
кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
АКТИВНА СУБСТАНЦИЯ:
Фентанил
50 mg/ml
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Трансдермален разтвор.
Бистър, безцветен до леко жълт
разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОП
РЕДЕЛЕНИ ЗА ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
За контрол на следоперативната болка,
свързана с тежки ортопедични
хирургични операции и
хирургични операции на меки тъкани
при кучетата.
4.3
ПРОТИВОПОКАЗАНИЯ
Да не се прилага върху кожа, която няма
цялостен
_stratum corneum, _
поради нараняване или
заболяване.
Да не се прилага върху зони, различни
от дорзално-скапуларната об
ласт.
Да не се използва при кучета със
сърдечна недостатъчност, хипотензия,
хиповолемия,
дихателна недостатъчност,
хипертензия, предишни случаи на
епилепсия, патология на
роговицата, несвързана с възрастта
ил
                                
                                Read the complete document

Similar products

Active ingredient фентанил

фентанил

ATC code QN02AB03

QN02AB03

Marketed by Eli Lilly and Company Limited 

Eli Lilly and Company Limited 

INN (International Name) fentanyl

fentanyl

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 12-07-2017
Summary of Product characteristics Summary of Product characteristics Spanish 12-07-2017
Public Assessment Report Public Assessment Report Spanish 12-07-2017
Patient Information leaflet Patient Information leaflet Czech 12-07-2017
Summary of Product characteristics Summary of Product characteristics Czech 12-07-2017
Public Assessment Report Public Assessment Report Czech 12-07-2017
Patient Information leaflet Patient Information leaflet Danish 12-07-2017
Summary of Product characteristics Summary of Product characteristics Danish 12-07-2017
Public Assessment Report Public Assessment Report Danish 12-07-2017
Patient Information leaflet Patient Information leaflet German 12-07-2017
Summary of Product characteristics Summary of Product characteristics German 12-07-2017
Public Assessment Report Public Assessment Report German 12-07-2017
Patient Information leaflet Patient Information leaflet Estonian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Estonian 12-07-2017
Public Assessment Report Public Assessment Report Estonian 12-07-2017
Patient Information leaflet Patient Information leaflet Greek 12-07-2017
Summary of Product characteristics Summary of Product characteristics Greek 12-07-2017
Public Assessment Report Public Assessment Report Greek 12-07-2017
Patient Information leaflet Patient Information leaflet English 12-07-2017
Summary of Product characteristics Summary of Product characteristics English 12-07-2017
Public Assessment Report Public Assessment Report English 12-07-2017
Patient Information leaflet Patient Information leaflet French 12-07-2017
Summary of Product characteristics Summary of Product characteristics French 12-07-2017
Public Assessment Report Public Assessment Report French 12-07-2017
Patient Information leaflet Patient Information leaflet Italian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Italian 12-07-2017
Public Assessment Report Public Assessment Report Italian 12-07-2017
Patient Information leaflet Patient Information leaflet Latvian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Latvian 12-07-2017
Public Assessment Report Public Assessment Report Latvian 12-07-2017
Patient Information leaflet Patient Information leaflet Lithuanian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-07-2017
Public Assessment Report Public Assessment Report Lithuanian 12-07-2017
Patient Information leaflet Patient Information leaflet Hungarian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Hungarian 12-07-2017
Public Assessment Report Public Assessment Report Hungarian 12-07-2017
Patient Information leaflet Patient Information leaflet Maltese 12-07-2017
Summary of Product characteristics Summary of Product characteristics Maltese 12-07-2017
Public Assessment Report Public Assessment Report Maltese 12-07-2017
Patient Information leaflet Patient Information leaflet Dutch 12-07-2017
Summary of Product characteristics Summary of Product characteristics Dutch 12-07-2017
Public Assessment Report Public Assessment Report Dutch 12-07-2017
Patient Information leaflet Patient Information leaflet Polish 12-07-2017
Summary of Product characteristics Summary of Product characteristics Polish 12-07-2017
Public Assessment Report Public Assessment Report Polish 12-07-2017
Patient Information leaflet Patient Information leaflet Portuguese 12-07-2017
Summary of Product characteristics Summary of Product characteristics Portuguese 12-07-2017
Public Assessment Report Public Assessment Report Portuguese 12-07-2017
Patient Information leaflet Patient Information leaflet Romanian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Romanian 12-07-2017
Public Assessment Report Public Assessment Report Romanian 12-07-2017
Patient Information leaflet Patient Information leaflet Slovak 12-07-2017
Summary of Product characteristics Summary of Product characteristics Slovak 12-07-2017
Public Assessment Report Public Assessment Report Slovak 12-07-2017
Patient Information leaflet Patient Information leaflet Slovenian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Slovenian 12-07-2017
Public Assessment Report Public Assessment Report Slovenian 12-07-2017
Patient Information leaflet Patient Information leaflet Finnish 12-07-2017
Summary of Product characteristics Summary of Product characteristics Finnish 12-07-2017
Public Assessment Report Public Assessment Report Finnish 12-07-2017
Patient Information leaflet Patient Information leaflet Swedish 12-07-2017
Summary of Product characteristics Summary of Product characteristics Swedish 12-07-2017
Public Assessment Report Public Assessment Report Swedish 12-07-2017
Patient Information leaflet Patient Information leaflet Norwegian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Norwegian 12-07-2017
Patient Information leaflet Patient Information leaflet Icelandic 12-07-2017
Summary of Product characteristics Summary of Product characteristics Icelandic 12-07-2017
Patient Information leaflet Patient Information leaflet Croatian 12-07-2017
Summary of Product characteristics Summary of Product characteristics Croatian 12-07-2017

Search alerts related to this product

Alerts Recuvyra фентанил fentanyl

Recuvyra фентанил fentanyl

View documents history

Documents history Documents history

Recuvyra